Breast cancer at ASCO 2023: NATALEE and sequencing ADCs
Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of key updates in breast cancer from the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including the NATALEE Phase II trial (NCT03701334) which met its primary endpoint with a clinical meaningful benefit observed with ribociclib plus endocrine therapy in patients with early breast cancer. In addition, Dr Tarantino also discusses the findings of a retrospective analysis evaluating the sequencing of antibody-drug conjugates approved in the breast cancer space. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.